Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec;68(6):315-324.
doi: 10.1007/s12026-020-09154-4. Epub 2020 Oct 1.

Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development

Affiliations
Review

Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development

Daniela Calina et al. Immunol Res. 2020 Dec.

Abstract

During the COVID-19 pandemic in a modern era, there is a global consensus on the need for the rapid development of a vaccine against SARS-CoV-2 for effective and sustainable control. Developing these vaccines is fundamental to public health. This urgent need is supported by the scientific explosion in structural and genomic biology that facilitates the urgent development of an ideal COVID-19 vaccine, using new pathways to facilitate its large-scale development, testing, and manufacture. Here, we summarize the types of COVID-19 candidate vaccines, their current stage in early testing in human clinical trials, and the challenges for their implementation.

Keywords: COVID-19 pandemic; Candidate vaccines; Efficacy; Immunology; Public health; Quality; SARS-CoV-2; Safety.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Schematic mechanism of the neutralizing antibodies. Spike (S) protein binds to the host receptor (ACE2 receptor) and enter into the target cell through membrane fusion. The antibody targeting S protein can effectively block binding, membrane fusion, and entry of SARS-CoV-2 to the ACE2 receptor
Fig. 2
Fig. 2
Vaccines platforms and current status of potential candidate COVID-19 vaccines
Fig. 3
Fig. 3
A comparative scheme regarding the development of normal vaccines versus potential COVID-19 vaccines

References

    1. Docea AO, Tsatsakis A, Albulescu D, Cristea O, Zlatian O, Vinceti M, Moschos SA, Tsoukalas D, Goumenou M, Drakoulis N, Dumanov JM, Tutelyan VA, Onischenko GG, Aschner M, Spandidos DA, Calina D. A new threat from an old enemy: re-emergence of coronavirus. Int J Mol Med. 2020;45(6):1631–1643. - PMC - PubMed
    1. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J', Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. - PMC - PubMed
    1. Goumenou M, Sarigiannis D, Tsatsakis A, Anesti O, Docea AO, Petrakis D, Tsoukalas D, Kostoff R, Rakitskii V, Spandidos DA, Aschner M, Calina D. COVID-19 in Northern Italy: an integrative overview of factors possibly influencing the sharp increase of the outbreak. Mol Med Rep. 2020;22(1):20–32. - PMC - PubMed
    1. Tsatsakis A, Petrakis D, Nikolouzakis TK, Docea AO, Calina D, Vinceti M, Goumenou M, Kostoff RN, Mamoulakis C, Aschner M, Hernández AF. COVID-19, an opportunity to reevaluate the correlation between long-term effects of anthropogenic pollutants on viral epidemic/pandemic events and prevalence. Food Chem Toxicol. 2020;141:111418. - PMC - PubMed
    1. Adams ER, Augustin Y, Byrne RL, et al. Rapid development of COVID-19 rapid diagnostics for low resource settings: accelerating delivery through transparency, responsiveness, and open collaboration. medRxiv; 2020. 10.1101/2020.04.29.20082099.

MeSH terms

LinkOut - more resources